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Abstract 
Background: Despite increased efforts to control and ultimately eradicate human malaria, Plasmodium ovale malaria 
is for the most part outside the focus of research or public health programmes. Importantly, the understanding of P. 
ovale—nowadays regarded as the two distinct species P. ovale wallikeri and P. ovale curtisi—largely stems from case 
reports and case series lacking study designs providing high quality evidence. Consecutively, there is a lack of system-
atic evaluation of the clinical presentation, appropriate treatment and relapse characteristics of P. ovale malaria. The 
aim of this systematic review is to provide a systematic appraisal of the current evidence for severe manifestations, 
relapse characteristics and treatment options for human P. ovale malaria.
Methods and results: This systematic review was performed according to the PRISMA guidelines and registered in 
the international prospective register for systematic reviews (PROSPERO 2016:CRD42016039214). P. ovale mono-infec-
tion was a strict inclusion criterion. Of 3454 articles identified by the literature search, 33 articles published between 
1922 and 2015 met the inclusion criteria. These articles did not include randomized controlled trials. Five prospective 
uncontrolled clinical trials were performed on a total of 58 participants. P. ovale was sensitive to all tested drugs within 
the follow-up periods and on interpretable in vitro assays. Since its first description in 1922, only 18 relapsing cases 
of P. ovale with a total of 28 relapse events were identified in the scientific literature. There was however no molecular 
evidence for a causal relationship between dormant liver stages and subsequent relapses. A total of 22 severe cases of 
P. ovale malaria were published out of which five were fatal. Additionally, two cases of congenital P. ovale malaria were 
reported.
Conclusions: Current knowledge of P. ovale malaria is based on small trials with minor impact, case reports and clini-
cal observations. This systematic review highlights that P. ovale is capable of causing severe disease, severe congenital 
malaria and may even lead to death. Evidence for relapses in patients with P. ovale malaria adds up to only a hand-
ful of cases. Nearly 100 years after P. ovale’s first description by Stephens the evidence for the clinical characteristics, 
relapse potential and optimal treatments for P. ovale malaria is still scarce.
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Background
In 2015, 214 million new cases of clinical malaria 
accounting for around 438,000 deaths were identified 
worldwide [1]. Although these numbers are decreasing, 
they remain striking, as most were preventable. Malaria 
is among the “big three” infectious diseases and receives 
relatively much attention and funding. However, research 
focuses almost entirely on the most prevalent malaria 
parasite Plasmodium falciparum, whereas the other Plas-
modium species are widely neglected.
Plasmodium ovale has so far received comparatively lit-
tle attention in medical research. The primary focus after 
its first description by Stephens in 1922 was the character-
ization of its microscopic morphology [2–4]. Interestingly, 
it has been demonstrated recently by molecular methods 
that P. ovale essentially consists of two distinct sympatric 
species termed P. ovale curtisi and P. ovale wallikeri [5]. 
So far, only few clinical, epidemiological and therapeutic 
studies report specific data for P. ovale subspecies. How-
ever, based on molecular analysis the geographic distribu-
tion of P. ovale seems larger than previously thought [6, 7].
Although considered to induce only mild disease of minor 
importance, case reports indicate its potential of evoking 
severe disease and even death [8, 9]. A systematic evaluation 
of potential complications of P. ovale malaria is currently 
missing. Treatment of P. ovale was historically developed 
based on the empiric use of anti-malarial drugs admin-
istered for P. falciparum and Plasmodium vivax malaria. 
Since then, no systematic drug evaluation or development 
programme has been undertaken for P. ovale malaria.
One of the cornerstones of today’s understanding 
of ovale malaria is its potential to lead to hypnozoite 
induced relapse. This feature of tertian malaria is the 
reason for recommending the use of the antihypnozoite 
drug primaquine in P. ovale infections. Interestingly, this 
concept has been challenged recently based on a lack of 
experimental and clinical data supporting the hypnozoite 
model in ovale malaria [10–12].
These important gaps in the perception of the basic 
biology of P. ovale, of the potential to cause severe dis-
ease, of the evidence behind current treatment recom-
mendations and of its potential to cause relapse were the 
principal reasons to endeavor for a systematic evalua-
tion of all available evidence of P. ovale research since its 
description in 1922.
Methods
This systematic review was conducted following the 
PRISMA guidelines [13]. The protocol was registered at 
the international prospective register of systematic reviews 
(PROSPERO 2016:CRD42016039214). The scientific data-
bases MEDLINE, EMBASE, Cochrane Library, Scopus, 
CINAHL, Conference Proceedings Citation Index, Web of 
Science/Science Citation Index Expanded and DARE were 
searched for publications between 1922 and 2015 using 
“P. ovale” as search term. Additionally, Google Scholar 
was searched for publications between 1922 and 1971 to 
increase the coverage for the pre-internet era. Further-
more, ClinicalTrials.gov and the EU Clinical Trials Regis-
ter were checked for unpublished studies on P. ovale.
Data extraction
Screening, selection and data extraction were performed 
independently by the first and the second author. Disagree-
ments and uncertainties at any stage of the process were dis-
cussed and resolved by consensus. If needed, the last author 
was consulted for a final decision. Only English, German 
and French articles were included in this analysis unless 
there was clear indication for relevant information of pub-
lications in other languages. Full texts of potentially relevant 
articles were obtained and articles from other sources were 
included in the pool of articles. Articles were matched to 
three different categories: treatment, severity and relapse.
Plasmodium ovale mono-infection of a human subject, 
defined by diagnosis based on microscopy and/or polymer-
ase chain reaction (PCR) was a strict eligibility criterion 
for all categories. Additionally, separate definitions as fol-
lows were applicable for each category. Case reports were 
not used for treatment evaluation, otherwise there were no 
inclusion restrictions regarding types of studies. For in vitro 
studies, only assays with interpretable results were consid-
ered. Severe P. ovale malaria was determined on the basis 
of the 2014 WHO criteria for severe falciparum malaria 
[14] and other serious or life threatening clinical conditions 
as defined by the authors. As parasite counts are generally 
lower in severe P. ovale than in severe P. falciparum malaria 
[7] no threshold was determined for parasitaemia. A 
relapse was defined as a reappearing P. ovale parasitaemia 
following an initially diagnosed and adequately treated P. 
ovale “primary infection” (regardless of 8-aminoquinoline 
application) and subsequent permanent residence in a non-
endemic country. The term “primary infection” was used to 
describe the first reported P. ovale infection in the article, 
which was adequately treated (important for malaria infec-
tion studies, where patients were mostly not treated in case 
of self-limiting infection). The period between primary 
infection and relapse and two relapse events, respectively, 
was counted as time between the date of treatment and the 
first mentioned date of reappearance. In order not to con-
fuse delayed primary attacks with relapses, articles where 
the primary infection was not explicitly stated to have been 
a P. ovale infection were excluded.
Outcomes
Primary outcomes were adequate clinical and parasitolog-
ical response on day 28, frequency of severe complications 
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and the number of reported true relapses. Secondary out-
comes were to obtain relapse characteristics, treatment 
regimen used, parasite clearance time (PCT), fever clear-
ance time (FCT) and treatment outcome.
Data synthesis and risk of bias assessment
References were compiled in EndNote X6 (Thomson 
Reuters) and extracted data was collected in a standard-
ized Microsoft® Excel® 2013 datasheet. Descriptive sta-
tistics were performed using IBM® SPSS® Statistics 20. 
Applicable risk of bias was assessed in applicable stud-
ies using the Cochrane collaboration’s tool for assess-
ing risk of bias in combination with the methods guide 
for comparative effectiveness reviews [15, 16]. To assess 
overall quality of reporting an evaluation tool was cre-
ated uniformly for all included study designs following 
the study quality assessment of the case series studies 
tool of the National Institute of Health [17].
Results
Study selection
The search yielded 3454 publications. After elimina-
tion of duplicates and screening of available titles and 
abstracts for relevance, 212 articles were selected for 
full review (Fig. 1). Two articles were added from other 
sources and a total of 36 articles met the required 
Fig. 1 PRISMA [13] adapted flow diagram
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criteria. Of this pool, two articles reporting severe cases 
were excluded due to incomplete data and one because of 
double reporting, leaving 33 articles for data extraction.
No report was rated as having a low risk of bias due 
to the underlying study design. There were many case 
reports which made the systematic review especially vul-
nerable to selection bias and publication bias. To deal 
with publication bias, results from Clinical Trial Registers 
were included. As data were not used for a meta-analysis, 
missing data items did not influence individual risk of 
bias assessment. Individual risk of bias within studies as 
well as completeness of reporting are given in the Addi-
tional files 1, 2 and 3.
Study population
The study population of the included articles was het-
erogeneous. It consisted of residents in malaria-endemic 
areas, individuals visiting friends or relatives (VFRs), 
tourists, professionals temporarily residing in endemic 
countries, neurosyphilis patients treated with iatrogenic 
malaria infection, experimental malaria infections and 
one case of malaria transmission by blood transfusion. 
Study designs were diverse, but lacked designs judged to 
provide high quality evidence. There were no randomized 
controlled clinical trials (RCTs) and small sample size 
case series and case reports dominated the findings. The 
majority of reports did not distinguish between the two 
sympatric P. ovale species.
Not all endemic areas of the world were represented by 
the data that was found. The majority of cases was from 
sub-Saharan Africa. Asia was represented by Indonesia, 
Papua New Guinea and India. There were no eligible P. 
ovale reports from South America. Detailed informa-
tion about treatment, severe disease and relapse is subse-
quently described.
Treatment
The literature search yielded five prospective studies 
evaluating treatment for P. ovale in a total of 58 partici-
pants. Baseline characteristics are outlined in Table  1. 
One study was conducted in Indonesia [18], two in 
Cameroon [19, 20], one in Gabon [21] and one in France 
on returnees from sub-Saharan Africa [22]. One trial 
was exclusively designed for P. ovale infected individuals 
[19]. Artesunate, atovaquone, chloroquine, mefloquine 
and pyronaridine were used as study drugs. Two pro-
spective clinical trials with 13 participants in total chose 
chloroquine as study drugs [18, 21]. In general, sample 
sizes were small and control groups were missing in all 
5 prospective studies. In fact, the largest study recruiting 
30 patients evaluated artesunate therapy. Although the 
authors classified it as randomized trial, neither a placebo 
group nor a second treatment arm were described [19].
The longest follow-up period was 28  days, therefore, 
treatment success could not be obtained for days 42 and 
63. Besides Siswantoro et  al. (eight male, three female) 
[18], no publication reported the participants’ sex. For 
further details see Table 2. Two clinical trials additionally 
performed in vitro drug sensitivity testing. Interpretable 
assays showed no resistances of P. ovale against amodi-
aquine, artesunate, chloroquine, mefloquine, piperaquine 
or pyronaridine [18, 20].
Description of complicated and severe P. ovale malaria
Twenty two cases of severe P. ovale malaria were identi-
fied in scientific literature. Nigeria was the most com-
monly reported place of potential infection in travel 
histories (4 times) followed by Ghana, Cameroon and the 
Democratic Republic of Congo (3 times), and Ivory Coast 
and Niger (twice). The only non-African country report-
ing a complicated disease course was India (once). Mean 
age was 35.8 ± 13.6 years standard deviation (SD), with 
a range from 17 to 75  years. Fourteen cases were male, 
six female, for two sex was unknown. In Table 3, baseline 
characteristics are displayed in more detail. In 15 cases, P. 
ovale was diagnosed by microscopy. Seven patients were 
diagnosed by microscopy and PCR, out of which 2 cases 
were microscopically negative with a positive PCR result 
[24]. Species specific PCR was performed for four cases. 
Two were positive for P. ovale curtisi [8, 24], 1 for P. ovale 
wallikeri and for 1 species differentiation could not be 
deducted from the article [24, 25].
Table 1 Baseline characteristics in prospective uncontrolled clinical trials
No number, M male, F female, R resident, T tourist, – not mentioned in the original publication
Authors No of P. ovale cases Age (years) Sex Patients’ status Origin of infection
Siswantoro et al. [18] 11 28 (median) 8 M, 3 F R Indonesia
Same-Ekobo et al. [19] 30 – – R Cameroon
Ringwald et al. [20] 8 17 (median) – R Cameroon
2 8 (median) – R Cameroon
Radloff et al. [21] 3 >10 years – R Gabon
Danis et al. [23] 4 19–32 – T Sub-Saharan Africa
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For the 22 patients with severe clinical conditions, 15 
different features of severity could be identified. Tak-
ing the patients together, 35 severe conditions were 
reported. Acute respiratory distress syndrome (ARDS) 
was reported in five patients and therefore was the most 
prevalent severe condition. It was followed by anaemia 
with a hemoglobin level <7 g/dl, and pulmonary edema 
which occurred in 4 patients. 5 of the reported cases died 
and 3 patients had organic sequelae, however, 64% of the 
reported cases (n =  14) survived without sequelae. The 
majority of deaths occurred following onset of ARDS. 
Further details are displayed in Table 4.
Congenital malaria
Besides the clinically severe cases described above, two 
independent cases of congenital P. ovale malaria were 
identified presenting with severe anaemia [26, 27]. The 
two mothers (both secundigravidae) had resided in an 
African country prior to birth but gave birth to their chil-
dren in Europe and also remained there during the obser-
vation period. Both had a history of treated malaria of 
unknown species. The respective children were delivered 
by Cesarean, one because of a treated human immuno-
deficiency virus (HIV) infection of the mother, the other 
one as an emergency cesarean section. Being healthy at 
birth, malaria was diagnosed 5 and 3 weeks post-partum. 
Detailed information is presented in Table 5.
Relapse
From the description of P. ovale as distinct species in 
1922 up to 2015 a total of 18 cases with potentially 
relapsing P. ovale parasitaemia according to the inclusion 
criteria applied for this systematic review were reported 
in scientific literature. These patients were described to 
have experienced a total of 28 potential relapse events. 
4 cases (22%) occurred in tourists, 14 (78%) in malaria 
infection studies. Sex was specified in 44% of the patients, 
all of them were male. Fever was mentioned in five epi-
sodes, other clinical information about relapse charac-
teristics was missing. The most commonly used drugs to 
treat primary infections and relapses were chloroquine 
and quinine sulfate. Median time between primary infec-
tions and first potential relapses was 17 weeks (min–max 
2–60 weeks). The median time between first and second 
potential relapse was also 17  weeks, ranging from 5 to 
72 weeks. The time between second and third relapse was 
not reported. Six relapses occurred despite previous pri-
maquine treatment. Eight individuals presented with two 
relapses and one individual relapsed three times. Details 
can be found in Tables 6 and 7.
Diagnostics relied exclusively on microscopy. PCR 
correction of the infective species was not performed. 
Furthermore, there were no articles proving a causal rela-
tionship between dormant liver stages and reappearances 
of P. ovale infections in the human host.
Table 2 Treatment characteristics
MIC microscopy, PCR polymerase chain reaction, Y yes, –not mentioned in the original publication, ~ adequate clinical and parasitological response of P. ovale at day 
28, however, reappearing P. vivax in follow up period at days 14 and 23
Authors Diagnos‑
tics


















– 24 48 Y~ 28
Same-Ekobo 
et al.
MIC 534,642 p/µl 
(total)







cytes in 1 
participant











45 57 Y 14
MIC 6656–13,680 
p/µl
Chloroquine 25 mg/kg Over 
3 days
– 24 60 Y 14






– – 72–168 Y 28
Danis et al. – – Mefloquine 0.5–1.25 mg Once and 
twice
– – 72–120 Y –
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Discussion
Several small literature reviews focusing on specific but 
limited aspects of P. ovale malaria have been previously 
published, most often appended to case reports. The 
epidemiology of ovale malaria in a high endemic setting 
has been demonstrated with long-term surveillance data 
[34, 35]. P. ovale has also been addressed in the context of 
other infectious diseases [36, 37]. However, to date, the 
scientific literature does not provide a systematic over-
view focusing on clinical, therapeutic and relapse charac-
teristics of P. ovale. As to the dimorphism of P. ovale, too 
few articles distinguished between the sympatric species 
to suggest potential differences. This systematic review 
therefore combines data from both P. ovale species.
Evaluation of current treatment recommendations
Chloroquine has been the recommended treatment for 
P. ovale malaria for many years. In the latest guideline 
for the treatment of malaria, the WHO strongly recom-
mends to treat P. ovale and other non-falciparum Plas-
modium species with artemisinin-based combination 
therapy or chloroquine on the basis of “high-quality 
evidence”. Following elaborations of underlying stud-
ies in the WHO guideline however rather break this 
down to experience [38]. In this systematic review, no 
high-quality studies supporting current treatment rec-
ommendations were identified. Not a single randomized 
controlled clinical trial on P. ovale malaria has been pub-
lished in scientific literature. This finding is supported by 
a report by Visser et al. [37]. Although chloroquine has 
been tested in small prospective uncontrolled trials, one 
might question whether this small number of partici-
pants and a lack of control groups in all studies provide 
enough evidence for unequivocal treatment recommen-
dations. Summing up all published reports and clinical 
experience, it becomes evident that anti-malarial drugs 
employed for P. falciparum are also effective for P. ovale. 
However, scientifically sound evidence for this is cur-
rently missing.
Severe disease
In 1932, James and coworkers stated that it was unlikely 
that another malignant species besides P. falciparum 
would be discovered [39]. Since then Plasmodium 
knowlesi was found to be infective for humans leading to 
life-threatening quotidian malaria. Also the previously 
considered benign malaria species P. malariae, P. vivax 
and P. ovale were reported to cause severe disease and 
even death in a small minority of patients. To date little 
is known on the specific pathogenesis of severe diseases 
Table 3 Baseline characteristics of severely diseased P. ovale cases
M male, F, female, T tourist, R resident, W work, B blood transfusion, V visiting friends or relatives, NA not applicable, – not mentioned in the original publication
Authors, year of publication Age Sex Patient status Travel history Chemoprophylaxis
Tomar et al. [61], 2015 75 M R None, resident of India NA
Lemmerer et al. [62], 2015 29 M W Democratic Republic of Congo –
Strydom et al. [36], 2014 42 M W Guinea, Mozambique None
Rojo-Marcos et al. [24], 2014 17 F – – –
31 M – – –
Lau et al. [8], 2013 59 M T Nigeria Mefloquine
Hachimi et al. [42], 2013 31 M – Democratic Republic of Congo –
Lahlou et al. [41], 2012 28 M W Democratic Republic of Congo –
Roze et al. [63], 2011 24 M W Chad, Ivory Coast Doxycycline
Coton et al. [64], 2011 33 M W Djibouti –
Haydoura et al. [65], 2010 46 F B NA NA
Cinquetti [66], 2010 34 M W Ivory Coast, Senegal Doxycycline
Rojo-Marcos et al. [25], 2008 43 M V Nigeria None
Rubinstein et al. [67], 2005 23 M – Nigeria –
Filler et al. [68], 2003 39 F T Cameroon, Botswana, Zimbabwe, South Africa Yes, drug unknown
Lee et al. [69], 1999 31 F T Ghana Mefloquine
Patel [70], 1993 42 M T Central and southern Africa NA
Facer et al. [9], 1991 51 F T Ghana None
Monlun, et al. [71], 1989 38 M T Niger Chloroquine
Bock [72], 1939 23 – W Western Africa, Cameroon Chinoplasmine
20 – W Western Africa, Cameroon Quinine (irregular)
Fairley [73], 1933 28 M T Nigeria, Ghana, Gambia, Sierra Leone Quinine
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in these non-falciparum malarias. The results of this sys-
tematic review support this understanding.
It is of interest that ARDS was the main feature of 
severe disease in P. ovale malaria as it was described in 
returning travellers with P. vivax malaria [40]. The poten-
tial coincidence that the two patients with a history of 
tuberculosis 10 years and more ago both died from ARDS 
raises the question whether a preexisting pulmonary con-
dition may be a risk factor for respiratory complications 
of P. ovale infection [41, 42]. Anaemia was also reported 
as a feature of severe P. ovale malaria, however due to its 
multifactorial aetiology it is difficult to attribute this with 
confidence to P. ovale infection. Nevertheless it has been 
reported concordantly in paediatric patients with P. vivax 
infection in Asia [43].
An important limitation in the description of severe 
cases of P. ovale infection is the only partly performed 
molecular assessment of blood samples. Although light 
microscopy forms the current gold standard for malaria 
diagnostics, its sensitivity is inferior to most molecular 
methods. Additionally, species determination and dis-
tinction, especially between P. ovale and P. vivax can be 
challenging most notably in low parasitaemic smears [44, 
45]. It is, therefore, not possible to entirely exclude the 
possibility of coinfection with other Plasmodium species 
including P. falciparum in these cases.
Congenital malaria is a rare finding in non-endemic 
countries. Even more surprising was the identification 
of two cases of congenital P. ovale malaria with severe 
anaemia in Europe. Both mothers had been living in an 
endemic country in the past. Interestingly, one of the 
infants was born to a HIV positive mother. An associa-
tion between HIV and the incidence of P. falciparum in 
pregnancy has already been shown [46] and it might be 
speculated that the same is true for P. ovale. In 2008, Vot-
tier et  al. reported another congenital P. ovale infection 
transmitted by an HIV positive mother which was how-
ever not severe [47].
The concept of hypnozoite‑induced relapse in P. ovale 
malaria
Although the concept of hypnozoite-induced relapse in 
all tertian malarias seemed as a unanimous concept until 
recently, molecular evidence supportive for this model 
is scarce. A recent experimental study in mice engrafted 
with human hepatocytes observed uninucleate parasitic 
structures measuring  ~5  µm (day 8) and late schizonts 
(day 21) after P. ovale sporozoite inoculation [48, 49]. The 
description of these histological structures resembles the 
findings of Krotoski described for Plasmodium cynomolgi 
bastianelli in Rhesus monkeys (average diameter 4.5 µm) 
and for P. vivax in chimpanzees (approximately 4–5 µm 
Table 6 Baseline characteristics of potentially relapsing patients








Bottieau [28], 2005 T 17 M Ghana Mefloquine –
T 22 M Nigeria Mefloquine –
T 14 M Uganda None –
Collins et al. [29], 2002 I – – NA NA 3780
I – – NA NA 2220
I – – NA NA 8560
I – – NA NA 9810
I – – NA NA 5376
Nathwani et al. [30], 1991 T 24 M Papua New Guinea Chloroquine, pyrimeth-
amine
–
Chin et al. [31], 1971 E – M NA NA –
E – M NA NA –
E – M NA NA –
E – M NA NA –
E – M NA NA –
Garnham et al. [32], 1955 I – – NA NA –
I – – NA NA –
Jeffery [33], 1954 I – – NA NA –
I – – NA NA –
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diameter) [50, 51]. However, this analogy does not consti-
tute proof that these uninucleate structures truly repre-
sent hypnozoites or rather retarded forms. Furthermore 
it does not provide evidence for these structures to cause 
relapse events [48]. Based on this lack of firm experimen-
tal evidence and the scarcity of clinical reports a recent 
perspective article challenged the current concept of P. 
ovale relapse caused by liver hypnozoites proposing a 
gradual dormancy concept [52].
The presence of dormancies as such can be assumed 
as data from malaria elimination settings suggests their 
important role for sustained malaria transmission, along 
with P. vivax [53].
Plasmodium ovale hypnozoites have not yet been 
unequivocally demonstrated in the human host. As evi-
denced by this systematic review a total of 18 reported 
cases of P. ovale relapse in nearly 100 years do not pro-
vide solid evidence for the current relapse theory. On 
the other hand, experiments and malaria treatment of 
neurosyphilis patients have shown that in case of repeti-
tive inoculation with the same strain, immunity to this 
homologous challenge develops fast and subsequent 
infections remain often asymptomatic [54, 55]. Hence, it 
may be speculated that a true relapse may lead to miti-
gated symptoms or may even be sub-clinical.
In this context, it is of interest to note that six poten-
tial relapses occurred despite previous primaquine 
treatment. However, intake of primaquine has not been 
evaluated in these patients.
Historically, the concept of treatment of P. ovale relapses 
with an 8-aminoquinoline is based on the observation that 
quinine and pamaquine (the first synthetic 8-aminoquino-
line) together were more effective in the treatment of cer-
tain malaria cases than quinine alone. When Sinton and 
Bird observed that pamaquine reduced the relapse rate of 
P. vivax malaria [56] several 8-aminoquinoline derivatives 
were synthesized and tested for this purpose. Primaquine 
finally showed a higher anti-relapse effect than pamaquine 
with reduced toxicity among the most promising sub-
stances, but effectiveness for P. ovale relapses has since 
then only been presumed and never demonstrated [57]. 
Importantly, from a methodological point of view, to prove 
the effectiveness of a medication it is necessary to first 
unequivocally demonstrate the existence of the condition 
to be treated—in this case hypnozoite-induced relapse.
Richter et  al. questioned the existence of relapses in 
P. ovale in a review in 2010. They stated that “it may be 
difficult to differentiate a true relapse from a primary 
malaria attack with a long latency” [10]. To overcome 
that difficulty, the analysis was restricted to cases, which 
did not reside in a malaria endemic area between the 
occurrences of primary infection and relapse. In addition, 
the species of the primary infection had to be explicitly 
mentioned to be P. ovale and treated with anti-malarial 
chemotherapy. Comparing the results of this systematic 
review with those of Richter et al. [52], these strict crite-
ria are the main reason why even fewer cases of potential 
relapses were observed here.
Finally, only one potential case of relapse that was 
investigated with molecular methods could be identi-
fied in the literature [58, 59]. As this case occurred in 
an endemic area, the report did not fit the criteria of 
this systematic review and was therefore not included 
in the primary analyses. After personal communication 
with one of the authors (Fuehrer) the confirmation for 
this potential relapse case was based on the sequence 
homology of partial cox1, SSU rRNA, and porbp2 loci 
between the primary and the potential relapse isolate 
[60]. These markers are usually not used for intraspe-
cific distinction but for differentiation between the spe-
cies. The multigene approach, however, enhances the 
significance of the result. In summary, the identifica-
tion of highly sensitive genetic markers or techniques 
that can discriminate between hypnozoite induced 
relapse and other sources of recurrent infections is still 
a work in progress.
Limitations of this systematic review are the low 
strength of evidence of the included studies based on 
their study design. At the same time, they form the only 
available evidence to address the review questions and 
form the basis of current recommendations.
Conclusion
In conclusion, this review of the scientific literature 
between 1922 and 2015 did not reveal a single high qual-
ity randomized controlled clinical trial. The reported evi-
dence indicates that P. ovale is capable of evoking severe 
disease, severe congenital malaria and even death. Evi-
dence for P. ovale related recommendations, however, 
seems to be scarce and is often based on clinical experi-
ence rather than on solid scientific evidence. Accordingly, 
this underlines the importance for clinical trials with 
larger sample size to obtain the efficacy of several treat-
ment options for P. ovale.
Evidence for relapses in P. ovale malaria is poor. 
Relapses in the human host have so far only once been 
studied with molecular methods. Hence, there is a need 
to further explore the P. ovale relapse theory and find 
scientifically sound evidence that proves or disproves 
the existence of relapses and of hypnozoites as origin of 
such potential P. ovale relapse events. With that knowl-
edge, one might also gain a new perspective on the ade-
quate management for the radical cure of tertian ovale 
malaria—a neglected malaria, which in the future may 
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gain in public health importance in the setting of success-
ful elimination campaigns for falciparum malaria.
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